,一是设计once-weekly的GLP-1受体激动剂,即Semaglutide (司美格鲁肽,旧称索马鲁肽) ,二是Semaglutide的口服化,但口服版的司美格鲁肽并不是once-weekly给药,而是一日一次,图中的标题似乎容易引起混淆。 背景可能不用多介绍了,司美格鲁肽从老本行降糖开始,兼有心...
作为一周一次给药的重磅GLP-1产品,诺和泰®以突破性技术将半衰期延长至7天,实现一周一次给药,强效控糖、精准达标,并以全面心血管代谢获益,为中国2型糖尿病患者提供更加有效、简便、安全的治疗选择。 原文出处: Wegovy™ (semaglu...
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024 Mar;12(3):184-195. doi: 10.1016/S2213-8587(23)...
概括地讲,这些人源长效GLP-1药物的共同特征是运用基因工程技术使GLP-1类似物与人体的免疫球蛋白IgG(FC片段)或者人体白蛋白(albumin)融合或结合,使其在体内避免快速被肾脏清除和代谢降解,延长半衰期。 杜拉鲁肽为GLP-1与人IgG4-Fc连接的融合蛋白,由将GLP-1类似物的N-末端与经过修饰的人IgG4重链Fc段,通过一个...
2.R. R. Holman, M. A. Bethel, R. J. Mentzet al., Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med377, 1228-1239 (2017). 3.https://professional.diabetes.org. 4.https://www.easd.org. ...
3.Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, et.al, Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial, Lancet Diabetes Endocrinol 2018 4.Juan P. Frias, M.D., Melanie J. Davies, M.D., Julio Ros...
13. Ji L. Basal insulin intensification by switching to once-weekly IcoSema (COMBINE 1). Presented at EASD 2024 Annual Meeting. S40. 14. Lingvay I. Intensification with IcoSema in a GLP-1RA experineced population (COMBINE 2). Presented at EASD 2024 Annual Meeting. S40. ...
[6]https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/clinical-trial-1-results.html [7] Jastreboff A M, Aronne L J, Ahmad N N, et al. Tirzepatide once weekly for the treatment of obesity[J]. New England Journal of Medicine, 2022, 387(3): 205-216.[8] ...
Consider Ozempic® (semaglutide) injection, a once-weekly GLP-1 RA therapy for your patients with T2D who need additional glycemic control. Read Important Safety and Prescribing Information, including Boxed Warning.